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Abstract
A tumefactive lesion of central nervous system (CNS) is defined as a mass-like 
lesion with a size greater than 2 cm in brain detected by magnetic resonance 
imaging (MRI). Neuroimaging may help to distinguish the nature of a 
tumefactive lesion and therefore, can prevent an unnecessary brain biopsy. Here 
we emphasized on determining the nature of a CNS tumefactive lesions with the 
help of MRI and more explanations about demyelinating lesions with focus on 
Schilder and Balo diseases as two multiple sclerosis variants. We have reported 
here two boys of 10 and 8 years of age respectively of multiple sclerosis (MS) 
variants who presented with acute neurologic complications to our hospital as one 
of the two referral children hospital in Tehran, Iran. Tumefactive demyelinating 
lesions can be considered a separate entity that itself can contain Schilder disease, 
Balo disease, some cases of acute disseminated encephalomyelitis (ADEM) or 
classic MS. MRI can help to establish a diagnosis of a tumefactive lesion and to 
differentiate among different underlying etiologies.
Keywords: Central Nervous System; Demyelination; Tumefactive Lesion; 
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Introduction
Magnetic resonance imaging (MRI) of the central nervous system (CNS) is 
essential for initial investigation of a child presented with acute or sub-acute focal 
neurologic problems, which may show a mass-like lesion. The four differential 
diagnoses of a tumefactive (mass-like) CNS lesion found on MRI are tumors and 
infiltrative lesions, vascular lesions, abscess/CNS parasitic infections and finally 
acquired demyelinating disorders (1, 2). 
Demyelinating diseases of the nervous system are divided into two major groups 
based on anatomical localization: demyelinating diseases of CNS and demyelinating 
diseases of peripheral nervous system (PNS). The major entities in the spectrum 
of CNS demyelinating diseases are classic multiple sclerosis (MS), MS variants 
(Schilder, Balo, Devic and according to some theories Marburg disease), acute 
disseminated encephalomyelitis (ADEM), acute hemorrhagic leukoencephalitis 
(Hurst Disease), optic neuritis, acute transverse myelitis (ATM), and acute cerebellar 
ataxia (ACA) (3). The most important disorders categorized in PNS demyelinating 
group are Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP). Features such as clinical presentation at disease 
onset, age at onset, course of the illness, number and location of the lesions in the 
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development referred to our hospital with sub-acute 
onset of right-circumduction gait, some degree of vision 
loss, expressive aphasia, vomiting and headache started 
from 1 month ago. There was no history of recent URI 
or vaccination. In physical examination, he had no fever 
but right foot drop and right arm weakness in association 
with bilateral downward plantar reflexes. Fundoscopic 
examination of the patient showed bilateral papilloedema 
(grade 2-3). Routine blood chemistries were normal.
Brain computed tomography CT scan had been performed 
elsewhere helped to implement CSF puncture unwarily. 
CSF analysis showed normal degree of protein, glucose, 
IgG index, lactate, oligoclonal band (CSF OCB) and 
negative AQP4 antibody. CSF opening pressure was 
about 28 cm H2O. Bacterial and viral assessments 
of CSF and CSF polymerase chain reaction PCR for 
tuberculosis were all negative. Serum very long-chain 
fatty acid (VLCFA) levels and adrenal function tests 
were normal. 
Initial brain MRI without contrast showed bilateral 
abnormal high signal lesions in the subcortical and 
deep posterior white matter in T2-WI sequence that was 
almost isointense with CSF in the center, surrounded by 
a peripheral halo (Figure 1a). In post contrast, T1-WI 
image show signal lesions with peripheral complete and 
incomplete ring enhancements were noted, suggesting 
necrotic or tumefactive center. Some cortical extension 
of the lesion located in the right posterior parietal 
lobe was remarkable (Figure 1b-d). The clinical 
course, atypical presentation, relative high opening 
pressure of CSF and radiologic findings in brain MRI 
with contrast suggested the probable diagnosis of the 
Schilder disease. The patient was treated with a 5-day 
course of methylprednisolone pulse (20 mg/kg/d). His 
clinical condition was bettered after 10 d and due to 
some neurologic residue such as hemiparesis and vision 
problem, oral prednisolone was continued for about 4 
months (1-2mg/kg) and then tapered. The patient was 
followed for about 2 yr and all of his symptoms was 
recovered, completely. He showed no disease flare-up 
during the follow-up period. We do not perform brain 
biopsy and MRS (magnetic resonance spectroscopy) 
for him and brain MRI with contrast after 2 yr of the 
onset of the disease showed just remaining residual 
hypersignal lesions in T2- FLAIR as a sequel of treated 
CNS imaging, previous medical or vaccination history 
and cerebrospinal fluid (CSF) characteristics, can help 
us to distinguish different types of these disorders (3).
Some cases of classic MS, MS variants such as Schilder 
or Balo disease and some cases of ADEM are the 
most important acquired demyelinating disorders that 
can produce tumefactive appearance in brain MRI. 
Simply, the presence or absence of fever and signs 
of encephalopathy, previous history of URI (upper 
respiratory infection) or vaccination as well as brain 
imaging finding scan help us to differentiate between 
ADEM and MS variants (3-8). Schilder and Balo diseases 
are rare MS variants that cause CNS demyelinating 
disorders. Since the histopathological features of these 
diseases are similar to MS, they are classified as MS 
variants, although their clinical features are different from 
MS to some degree (5, 6). Schilder and Balo diseases 
may look resembling in terms of clinical symptoms with 
each other, but neuroradiologic and pathologic features 
help to differentiate between them.
Correct diagnosis of the nature of a tumefactive lesion 
is important, preventing unnecessary brain biopsy, 
surgery or therapeutic procedures such as radiotherapy 
or chemotherapy (9). Nowadays, fortunately, different 
neuroradiologic methods help us to determine the nature 
of these lesions and in some cases; they eliminate the 
need for invasive procedures such as brain biopsy (4,10). 
Here, we emphasized the MRI finding of Schilder and 
Balo diseases presenting two real cases.
Case Report
Two patients (two boys with 10 and 8 years old) presented 
to our hospital as one of the two big referral children 
hospital in Iran with acute and subacute neurologic 
complications. Further medical evaluation revealed onset 
of acute tumefactive demyelinating disease in these two 
cases. We report clinical and laboratory findings of these 
two patients in details with a brief review of the role of 
neuroimaging modalities in how to manage tumefactive 
lesions in brain MRI. 
Consent form was written and filled by biologic parents 
of both two patients to include in our study.
Patient 1
The first case was a 10-yr-old boy with normal 
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had done 6 months after biopsy, demonstrated volume 
loss in the right hemisphere with secondary ventricular 
prominence. Mass-like lesion seen in the second brain 
MRI in the right frontal lobe could not be seen any longer 
and abnormal periventricular white matter signal would 
suggest diffuse gliotic changes or less likely sequel of 
previous demyelinating lesion (Figure 5a-d). The last 
brain MRI (2 yr after biopsy) had not any more changes 
as compared with third brain MRI (not shown here). The 
patient had no flare-up of similar symptoms or seizure 
recurrence during these 2 years of follow-up. 
Discussion
Normally, tumefactive demyelinating lesion is defined 
as a mass-like lesion with a size greater than 2 cm in 
brain MRI. Its radiologic features may include mass 
effect, local edema, ring enhancement and decreased 
relative cerebral blood volume (4, 9, 11, 12). However, 
tumefactive demyelinating lesion was occasionally 
defined as a lesion with a diameter of greater than 3 
cm (13). Sometimes, these lesions make a diagnostic 
uncertainty because they may be confused with an 
intracranial tumor. Other two important differential 
diagnoses of a tumefactive lesion in brain MRI in 
children are abscesses and vascular malformations (2). 
Tumefactive demyelinating lesions occur mainly in 
cerebral hemispheres but may be seen in other parts of 
CNS, such as cervical spinal segments (9,14). Between 
various types of demyelinating diseases, ADEM, some 
cases of classic MS and MS variants such as Schilder 
and Balo disease can present themselves with a pattern 
of tumefactive lesion in the brain MRI (9).
The onset of neurologic symptoms of tumefactive 
demyelinating lesions may be acute or subacute (9, 
10). These symptoms can include headache, vomiting, 
cognitive and behavioral changes, increased intracranial 
pressure, visual disturbance, optic neuritis, deafness, 
hemiparesis and or seizure (3,7,9). The first case 
(Schilder disease) presented with signs of increased Intra 
Cranial Pressure (ICP), hemiparesis and some degree of 
visual loss and speech problem (expressive aphasia). 
One of interesting signs in this patient less reported is 
speech problem. In addition, the second case (Balo 
disease) showed hemiparesis and seizure in his clinical 
course. Increased ICP have been reported in Schilder 
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demyelinating lesions (Figure 2a,b) and disappearance 
of tumefactive lesions in T1-WI (Figure 2c, d).
Patient 2
The second case was an 8-yr-old boy with normal 
development who presented with acute onset of left-sided 
hemiparesis of the face and subsequently weakness of 
left-side limbs following a mild head injury. He had no 
history of recent viral illnesses or vaccination. Physical 
examination revealed no loss of consciousness or fever, 
but he had left-sided limb paresis with hyperreflexia 
and central left facial nerve palsy. Other neurologic 
examinations were unremarkable. Brain CT scan with 
contrast demonstrated low attenuated subcortical areas 
in the right frontal lobe and right lentiform nucleus with 
some mass effect (Figure 3a). 
The first brain MRI of the patient showed a couple of 
hypersignal lesions in T2-WIsequence. The larger one 
was located in the right lentiform nucleus and insular 
subcortical white matter with surrounding halo. The 
smaller one was located in the posterior limb of right 
internal capsule (Figure 3b, 3c). Lumbar puncture 
revealed CSF protein of 10 mg/dl, negative oligoclonal 
band and AQP4 antibody and no CSF pleocytosis. 
Virology assessment of CSF for HSV, VZV and HIV 
were all-negative. The patient was treated with a 4-day 
course of methylprednisolone pulse with presumptive 
diagnosis of Balo disease. The clinical symptoms 
ameliorated, but due to remaining some degree of left-
sided limbs weakness, physical therapy was started. 
About 2 months later, he presented to the Emergency 
Department with an attack of a febrile seizure. After 
doing brain CT-scan, the second brain MRI was done 
that revealed very large mass like concentric or layered 
high signal lesion in FLAIR sequence in the right frontal 
lobe white matter and adjacent basal ganglia (Figure 4a, 
b).
 A brain biopsy of the right frontal lesion was done and 
showed a lesion with macrophage infiltration, prominent 
gemistocytic gliosis and no evidence of malignancy. 
These findings were compatible with a demyelinating 
disease and according to neuroradiologic findings, the 
diagnosis of Balo concentric sclerosis was considered. 
Carbamazepine was started for the patient and his 
clinical course followed for 2 yr. The third brain MRI 
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degree of edema around the lesions that do not involve 
subcortical U fibers (unlike ADEM) even in severe 
cases (2-4, 7, 14). Furthermore, in Schilder disease, 
unlike ADEM usually there is no history of recent viral 
illness or vaccination (15). The mainstay of its treatment 
is high dose of steroid that makes usually good clinical 
response. However, in one patient successful treatment 
with IVIG also has been reported (3,7). On the other 
hand, Balo disease mainly occurs in young adults and 
is more common in males (16). Its clinical course may 
be more severe than Schilder disease; although some 
cases of Balo disease with benign course have been 
reported (16-18). Neuropathologic features consisting of 
concentric rings of demyelination, alternating with rings 
disease (3). 
Schilder and Balo diseases are two rare demyelinating 
disorders of CNS that may have some similarity in 
clinical symptoms with each other, but neuroradiologic 
and pathologic findings help us to distinguish them 
from each other. The original case of Schilder disease 
was described by Schilder in 1912 but in 1986 Poser 
established revised diagnostic criteria for non-invasive 
diagnosis of true Schilder disease (2,4). Neuropathologic 
features of this disease that affect predominantly children 
or young patients are sharply demarcated giant coalescent 
plaques of demyelination that involve bilateral cerebral 
hemispheres. Imaging shows bihemispheric lesions of 
white matter with incomplete ring enhancement and some 
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Table 1. Characteristic Features of Brain Tumefactive Lesion (Its Differential Diagnosis) in Multiple 
Neuroradiologic Measures (22-27)
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20% of patients and it is associated with some dangers 
such as hemorrhage (4,10). This case had good clinical 
response to high-dose of methylprednisolone and oral 
prednisolone was continued and tapered off during 4 
months until full improvement of clinical condition of 
the patient. In the second case, neuropathologic and 
radiologic features were compatible with Balo disease. 
In this case, brain biopsy was done initially with probable 
diagnosis of brain tumor. The pathologic study of brain 
biopsy of this patient confirmed the diagnosis of Balo 
disease.
of normal white matter and imaging reveals lamellar 
and concentric pattern on proton and T2-weighted brain 
MRI images with alternating bands of enhancement and 
non-enhancement (19, 20).
Radiologic features of the first case in brain MRI were 
compatible with Schilder disease but we did not perform 
brain biopsy for neuropathologic evaluation. Based on 
criteria, histopathological evidence is necessary for 
diagnosis of Schilder disease (10). In recent years, the 
possibility of the diagnosis of this disease has been 
proposed by means of neuroradiologic measures in some 
reports because brain biopsy is not diagnostic in about 
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Fig  1. Initial brain MRI without contrast shows bilateral abnormal high signal lesions in the subcortical and deep 
posterior white matter in T2-WI sequence, almost isointense with CSF in the center, surrounded by a peripheral 
halo (a): After contrast injection In T1-WI images, low signal center with peripheral complete and incomplete ring 
enhancement is seen, suggesting necrotic or tumefactive center (b, c, d). Some cortical extension of the lesion in the 
right posterior parietal lobe is seen (Black arrow in d).
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It is worth determining the nature of tumefactive 
demyelinating lesions (TDL) by means of non-
invasive diagnostic tools, mainly neuroradiologic tools. 
Neuroimaging may help to prevent brain biopsy that 
is an invasive measure and is associated with some 
morbidity (0.7%-9%) and mortality (0%-1.2%) (10,14). 
In the second case, it was possible to reach the diagnosis 
of demyelinating lesion without brain biopsy, especially 
that the clinical symptoms of the patient ameliorated 
with trial course of steroid and the size of the lesions 
were decreased in the following brain MRI (compare 
Fig 4 and 5).
Different neuroradiologic measures can help us to 
characterize the nature of a TDL in brain MRI in a 
patient with focal neurologic deficit (Table 1) (21-26). 
These techniques in addition to brain MRI include 
MRS (Magnetic Resonance Spectroscopy), diffusion-
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weighted imaging (DWI) and perfusion-weighted 
imaging (PWI), apparent diffusion coefficient (ADC). 
Another way that can help to distinguish demyelinating 
nature of a tumefactive lesion from another differential 
diagnosis such as an abscess or neoplasm is good 
clinical response to steroid and reduction of the size of 
the lesions in serial neuroimaging (14).
In conclusion, demyelinating diseases of childhood 
have a wide clinical spectrum that can be divided into 
two groups that involve peripheral or central nervous 
system (3,5). We suggest among those who involve 
CNS, TDL can be considered a separate entity that itself 
can contain Schilder disease, Balo disease, some cases of 
ADEM or classic MS (27). In the absence of a biological 
marker, distinguishing of these disorders from each 
other can sometimes be difficult, but clinical course and 
use of neuroradiologic measures can help to establish a 
Fig 2. Brain MRI with contrast showed remaining hyper signal in T2- FLARE from sequel of treated demyelinating 
lesions (a,b) and just disappearance of tumefactive lesions in T1-WI (c,d) 
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Fig 3. Brain CT scan with contrast demonstrated low attenuated subcortical areas in the right frontal and right 
lentiform nucleus without significant mass effect or post contrast enhancement (a-White arrow). The first brain MRI 
of the patient showed a couple of hypersignal lesions in T2-WI. The larger one is located in the right lentiform nucleus 
and insular subcortical white matter with surrounding halo (Large white arrow-b). The smaller one was located in the 
posterior limb of right internal capsule (Small white arrow-c).
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    Fig  5. The third brain MRI has done 6 months after biopsy, demonstrated volume loss in the right hemisphere with 
secondary ventricular prominence. Mass like lesion in the second brain MRI in the right frontal lobe could not be seen 
any longer (a,b) and abnormal periventricular white matter signal would suggest diffuse gliotic changes or less likely 
sequel of previous demyelinating lesion (c,d).
Fig 4. The second brain MRI revealed very large mass like concentric or layered high signal lesion in FLARE 
sequence in the right frontal lobe white matter and adjacent basal ganglia
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